カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2018/05/08 | 1,357 | 1,369 | 1,335 | 1,352 | -19 | -1.4% | 128,900 |
2018/05/07 | 1,332 | 1,480 | 1,320 | 1,371 | +46 | +3.5% | 583,500 |
2018/05/02 | 1,310 | 1,335 | 1,304 | 1,325 | +3 | +0.2% | 55,500 |
2018/05/01 | 1,325 | 1,338 | 1,312 | 1,322 | -10 | -0.8% | 55,500 |
2018/04/27 | 1,332 | 1,349 | 1,327 | 1,332 | -4 | -0.3% | 40,300 |
2018/04/26 | 1,332 | 1,363 | 1,313 | 1,336 | +10 | +0.8% | 89,400 |
2018/04/25 | 1,349 | 1,367 | 1,326 | 1,326 | -33 | -2.4% | 92,200 |
2018/04/24 | 1,379 | 1,426 | 1,354 | 1,359 | ±0 | ±0% | 141,600 |
2018/04/23 | 1,360 | 1,375 | 1,341 | 1,359 | +12 | +0.9% | 78,300 |
2018/04/20 | 1,339 | 1,375 | 1,337 | 1,347 | -11 | -0.8% | 80,700 |
2018/04/19 | 1,399 | 1,409 | 1,353 | 1,358 | -45 | -3.2% | 78,800 |
2018/04/18 | 1,356 | 1,428 | 1,343 | 1,403 | +47 | +3.5% | 128,000 |
2018/04/17 | 1,402 | 1,425 | 1,310 | 1,356 | -59 | -4.2% | 263,800 |
2018/04/16 | 1,490 | 1,507 | 1,411 | 1,415 | -62 | -4.2% | 196,500 |
2018/04/13 | 1,454 | 1,487 | 1,448 | 1,477 | +9 | +0.6% | 138,600 |
2018/04/12 | 1,424 | 1,470 | 1,401 | 1,468 | +39 | +2.7% | 166,500 |
2018/04/11 | 1,474 | 1,499 | 1,422 | 1,429 | -12 | -0.8% | 222,000 |
2018/04/10 | 1,467 | 1,516 | 1,436 | 1,441 | -16 | -1.1% | 351,000 |
2018/04/09 | 1,456 | 1,490 | 1,415 | 1,457 | -13 | -0.9% | 263,400 |
2018/04/06 | 1,488 | 1,514 | 1,436 | 1,470 | -18 | -1.2% | 512,300 |
2018/04/05 | 1,551 | 1,568 | 1,461 | 1,488 | -49 | -3.2% | 937,400 |
2018/04/04 | 1,623 | 1,628 | 1,530 | 1,537 | -84 | -5.2% | 790,600 |
2018/04/03 | 1,720 | 1,735 | 1,601 | 1,621 | -59 | -3.5% | 835,300 |
2018/04/02 | 1,845 | 1,880 | 1,661 | 1,680 | -153 | -8.3% | 1,061,200 |
2018/03/30 | 1,810 | 1,909 | 1,706 | 1,833 | -17 | -0.9% | 1,905,100 |
2018/03/29 | 1,900 | 1,910 | 1,753 | 1,850 | +335 | +22.1% | 2,927,600 |
2018/03/28 | 1,515 | 1,515 | 1,515 | 1,515 | +300 | +24.7% | 69,300 |
2018/03/27 | 1,230 | 1,247 | 1,202 | 1,215 | -4 | -0.3% | 43,600 |
2018/03/26 | 1,205 | 1,221 | 1,157 | 1,219 | +15 | +1.2% | 60,900 |
2018/03/23 | 1,246 | 1,280 | 1,202 | 1,204 | -93 | -7.2% | 77,500 |
2018/03/22 | 1,299 | 1,310 | 1,286 | 1,297 | -2 | -0.2% | 22,300 |
2018/03/20 | 1,281 | 1,306 | 1,280 | 1,299 | -26 | -2% | 52,100 |
2018/03/19 | 1,331 | 1,332 | 1,282 | 1,325 | -9 | -0.7% | 60,400 |
2018/03/16 | 1,353 | 1,362 | 1,326 | 1,334 | -23 | -1.7% | 65,300 |
2018/03/15 | 1,372 | 1,376 | 1,337 | 1,357 | -15 | -1.1% | 93,400 |
2018/03/14 | 1,304 | 1,378 | 1,304 | 1,372 | +60 | +4.6% | 127,500 |
2018/03/13 | 1,278 | 1,329 | 1,278 | 1,312 | +22 | +1.7% | 51,800 |
2018/03/12 | 1,315 | 1,323 | 1,272 | 1,290 | -21 | -1.6% | 50,400 |
2018/03/09 | 1,323 | 1,352 | 1,305 | 1,311 | ±0 | ±0% | 70,000 |
2018/03/08 | 1,300 | 1,344 | 1,300 | 1,311 | +29 | +2.3% | 74,500 |
2018/03/07 | 1,290 | 1,313 | 1,257 | 1,282 | +9 | +0.7% | 71,900 |
2018/03/06 | 1,239 | 1,285 | 1,238 | 1,273 | +63 | +5.2% | 57,900 |
2018/03/05 | 1,295 | 1,307 | 1,204 | 1,210 | -80 | -6.2% | 92,600 |
2018/03/02 | 1,281 | 1,299 | 1,266 | 1,290 | -26 | -2% | 79,700 |
2018/03/01 | 1,287 | 1,319 | 1,265 | 1,316 | +7 | +0.5% | 84,000 |
2018/02/28 | 1,270 | 1,330 | 1,263 | 1,309 | +76 | +6.2% | 163,700 |
2018/02/27 | 1,290 | 1,293 | 1,232 | 1,233 | -37 | -2.9% | 85,200 |
2018/02/26 | 1,233 | 1,277 | 1,217 | 1,270 | +59 | +4.9% | 91,500 |
2018/02/23 | 1,216 | 1,230 | 1,199 | 1,211 | +9 | +0.7% | 24,800 |
2018/02/22 | 1,224 | 1,224 | 1,170 | 1,202 | -28 | -2.3% | 65,700 |
1601~
1650
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム